Want to see CNC full AI Analyst Report?
Gross Margin by Type
Shows profitability across various product types, indicating how well Centene manages costs and pricing strategies in different markets.Medicaid gross margin has weakened versus 2022 and only partially recovered into early‑2026, while Medicare and Commercial margins produced a sharp uptick in the latest quarter—the driver behind Centene’s EPS beat and raised outlook. That implies recent upside is more mix-, timing- and risk‑adjustment/receivable‑driven than a durable Medicaid turnaround; Medicaid still faces enrollment declines, mid‑single‑digit trend and specialty‑pharmacy pressure. The June Wakely data and pharmacy trend trajectory will determine if this margin improvement is sustainable.
Date | Medicaid | Medicare | Commercial | Other Eliminations |
|---|---|---|---|---|
Jun 30, 2026 | $1.39B | $1.17B | $1.95B | $117.00M |
Mar 31, 2026 | $1.62B | $1.55B | $2.36B | $120.00M |
Dec 31, 2025 | $1.61B | $378.00M | $497.00M | $74.00M |
Sep 30, 2025 | $1.53B | $538.00M | $1.12B | $159.00M |
Jun 30, 2025 | $1.12B | $863.00M | $946.00M | $92.00M |
Mar 31, 2025 | $1.43B | $1.20B | $2.54B | $110.00M |
Dec 31, 2024 | $1.37B | $729.00M | $1.59B | $115.00M |
Sep 30, 2024 | $1.48B | $675.00M | $1.74B | $120.00M |
Jun 30, 2024 | $1.46B | $645.00M | $2.27B | $155.00M |
Mar 31, 2024 | $1.94B | $546.00M | $2.07B | $175.00M |